Coagulation factor XIII serves as protein disulfide isomerase

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH08-09-0605
Issue:2009: 101/5 (May) pp. 795-990
Pages:840-844

Coagulation factor XIII serves as protein disulfide isomerase

Judith Lahav1*; Eli Karniel2*; Zsuzsa Bagoly3; Vera Sheptovitsky1; Rima Dardik4; Aida Inbal5
1Hemostasis Laboratory, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel; 2Internal Medicine Department B, Meir Hospital, Kfar Saba, Israel; 3Clinical Research Center, Haemostasis, Thrombosis and Vascular Biology Research Group of the Hungarian Academy of Sciences, University of Debrecen, Medical & Health Science Center, Debrecen, Hungary; 4Thrombosis and Hemostasis Unit, Sheba Medical Center, Tel Hashomer, Israel; 5Thrombosis and Hemostasis Unit, Department of Hematology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Israel

Summary

Tissue transglutaminase was reported to act as protein disulfide isomerase (PDI). We studied whether plasma transglutaminase – coagulation factor XIII (FXIII) – has PDI activity as well. PDI activity was measured by determining the ability to renature reduced- denatured RNase (rdRNase). We found that FXIII can renature rdRNase, with efficiency comparable to commercial PDI. This PDI activity was inhibited by bacitracin. Like tissue transglutaminase, FXIII-mediated PDI activity is independent of its transglutaminase activity and is located on the A subunit. Surface-associated PDI has been previously shown to catalyse two distinct functions: transnitrosation with subsequent release of intracellular nitric oxide and disulfide bond rearrangement during platelet integrin ligation. Our results imply that FXIII-PDI activity may have a role in platelet function.

Keywords

factor XIII, Transglutaminase, PDI

DOI

http://dx.doi.org/10.1160/TH08-09-0605

You may also be interested in...

1.

Zsuzsa Bagoly1,2, Ferenc Fazakas2, István Komáromi2, Gizella Haramura1, Eszter Tóth2, László Muszbek1,2

Thrombosis and Haemostasis 2008 99 4: 668-674

http://dx.doi.org/10.1160/TH07-09-0577

2.

Masayoshi Souri1, Shiori Koseki-Kuno1, Naoki Takeda2, Mitsunori Yamakawa3, Yasuchika Takeishi4, Jay L. Degen5, Akitada Ichinose1

Thrombosis and Haemostasis 2008 99 2: 401-408

http://dx.doi.org/10.1160/TH07-10-0599

3.

Zsuzsa Bagoly, Gizella Haramura, László Muszbek

Thrombosis and Haemostasis 2007 98 2: 359-367

http://dx.doi.org/10.1160/TH07-02-0098



Articles

You've 226 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...